Journal of Clinical Endocrinology & Metabolism, Vol 81, 3654-3662, Copyright © 1996 by Endocrine Society

ARTICLES

Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men--a clinical research center study

C Wang, DR Eyre, R Clark, D Kleinberg, C Newman, A Iranmanesh, J Veldhuis, RE Dudley, N Berman, T Davidson, TJ Barstow, R Sinow, G Alexander and RS Swerdloff
Department of Medicine, Harbor-University of California-Los Angeles Medical Center, Torrance 90509-2910, USA. WANG@HARBOR6.HUMC.EDU

To study the effects of androgen replacement therapy on muscle mass and strength and bone turnover markers in hypogonadal men, we administered sublingual testosterone (T) cyclodextrin (SLT; 5 mg, three times daily) to 67 hypogonadal men (baseline serum T, < 8.4 nmol/L) recruited from 4 centers in the U.S.: Torrance (n = 34), Durham (n = 12), New York (n = 9), and Salem (n = 12). Subjects who had received prior T therapy were withdrawn from injections for at least 6 weeks and from oral therapy for 4 weeks. Body composition, muscle strength, and serum and urinary bone turnover markers were measured before and after 6 months of SLT. We have shown previously that this regimen for 60 days will maintain adequate serum T levels and restore sexual function. Total body (P = 0.0104) and lean body mass (P = 0.007) increased with SLT treatment in the 34 subjects in whom body composition was assessed. There was no significant change in total body fat or percent fat. The increase in lean body mass was mainly in the legs; the right leg lean mass increased from 8.9 +/- 0.3 kg at 0 months to 9.2 +/- 0.3 kg at 6 months (P = 0.0008). This increase in leg lean mass was associated with increased leg muscle strength, assessed by leg press (0 months, 139.0 +/- 4.0 kg; 6 months, 147.7 +/- 4.2 kg; P = 0.0038). SLT replacement in hypogonadal men led to small, but significant, decreases in serum Ca (P = 0.0029) and the urinary calcium/creatinine ratio (P = 0.0066), which were associated with increases in serum PTH (P = 0.0001). At baseline, the urinary type I collagen-cross linked N-telopeptides/creatinine ratio [75.6 +/- 7.9 nmol bone collagen equivalents (BCE/mmol] was twice the normal adult male mean (41.0 +/- 3.6 nmol BCE/mmol) and was significantly decreased in response to SLT treatment at 6 months (68.2 +/- 7.7 nmol BCE/mmol; P = 0.0304) without significant changes in urinary creatinine. Serum skeletal alkaline phosphatase did not change. In addition, SLT replacement caused significant increases in serum osteocalcin (P = 0.0001) and type I procollagen (P = 0.0012). Bone mineral density did not change during the 6 months of SLT treatment. We conclude that SLT replacement therapy resulted in increases in lean muscle mass and muscle strength. Like estrogen replacement in hypogonadal postmenopausal females, androgen replacement therapy led to decreased bone resorption and urinary calcium excretion. Moreover, androgen replacement therapy may have the additional benefit of increasing bone formation. A longer term study for several years duration would be necessary to demonstrate whether these changes in bone turnover marker levels will result in increased bone mineral density decreased fracture risks, and reduced frailty in hypogonadal men.

This article has been cited by other articles:

				C. J. Malkin, P. J. Pugh, J. N. West, E. J.R. van Beek, T. H. Jones, and K. S. Channer Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial Eur. Heart J., January 1, 2006; 27(1): 57 - 64. [Abstract] [Full Text] [PDF]

				W. Gao, P. J. Reiser, C. C. Coss, M. A. Phelps, J. D. Kearbey, D. D. Miller, and J. T. Dalton Selective Androgen Receptor Modulator Treatment Improves Muscle Strength and Body Composition and Prevents Bone Loss in Orchidectomized Rats Endocrinology, November 1, 2005; 146(11): 4887 - 4897. [Abstract] [Full Text] [PDF]

				R. Jasuja, P. Ramaraj, R. P. Mac, A. B. Singh, T. W. Storer, J. Artaza, A. Miller, R. Singh, W. E. Taylor, M. L. Lee, et al. {Delta}-4-Androstene-3,17-Dione Binds Androgen Receptor, Promotes Myogenesis in Vitro, and Increases Serum Testosterone Levels, Fat-Free Mass, and Muscle Strength in Hypogonadal Men J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 855 - 863. [Abstract] [Full Text] [PDF]

				P. Szulc, F. Duboeuf, F. Marchand, and P. D Delmas Hormonal and lifestyle determinants of appendicular skeletal muscle mass in men: the MINOS study Am. J. Clinical Nutrition, August 1, 2004; 80(2): 496 - 503. [Abstract] [Full Text] [PDF]

				D. Vanderschueren, L. Vandenput, S. Boonen, M. K. Lindberg, R. Bouillon, and C. Ohlsson Androgens and Bone Endocr. Rev., June 1, 2004; 25(3): 389 - 425. [Abstract] [Full Text] [PDF]

				C. Wang, G. Cunningham, A. Dobs, A. Iranmanesh, A. M. Matsumoto, P. J. Snyder, T. Weber, N. Berman, L. Hull, and R. S. Swerdloff Long-Term Testosterone Gel (AndroGel) Treatment Maintains Beneficial Effects on Sexual Function and Mood, Lean and Fat Mass, and Bone Mineral Density in Hypogonadal Men J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2085 - 2098. [Abstract] [Full Text] [PDF]

				L. J. Woodhouse, N. Gupta, M. Bhasin, A. B. Singh, R. Ross, J. Phillips, and S. Bhasin Dose-Dependent Effects of Testosterone on Regional Adipose Tissue Distribution in Healthy Young Men J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 718 - 726. [Abstract] [Full Text] [PDF]

				P. Szulc, B. Claustrat, F. Marchand, and P. D. Delmas Increased Risk of Falls and Increased Bone Resorption in Elderly Men with Partial Androgen Deficiency: The MINOS Study J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5240 - 5247. [Abstract] [Full Text] [PDF]

				K. K. Lee, N. Berman, G. M. Alexander, L. Hull, R. S. Swerdloff, and C. Wang A Simple Self-Report Diary for Assessing Psychosexual Function in Hypogonadal Men J Androl, September 1, 2003; 24(5): 688 - 698. [Abstract] [Full Text] [PDF]

				I. Sinha-Hikim, S. M. Roth, M. I. Lee, and S. Bhasin Testosterone-induced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men Am J Physiol Endocrinol Metab, July 1, 2003; 285(1): E197 - E205. [Abstract] [Full Text] [PDF]

				R. A. Anderson, A. M. Wallace, N. Sattar, N. Kumar, and K. Sundaram Evidence for Tissue Selectivity of the Synthetic Androgen 7{alpha}-Methyl-19-Nortestosterone in Hypogonadal Men J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2784 - 2793. [Abstract] [Full Text] [PDF]

				L. J. Woodhouse, S. Reisz-Porszasz, M. Javanbakht, T. W. Storer, M. Lee, H. Zerounian, and S. Bhasin Development of models to predict anabolic response to testosterone administration in healthy young men Am J Physiol Endocrinol Metab, May 1, 2003; 284(5): E1009 - E1017. [Abstract] [Full Text] [PDF]

				T. W. Storer, L. Magliano, L. Woodhouse, M. L. Lee, C. Dzekov, J. Dzekov, R. Casaburi, and S. Bhasin Testosterone Dose-Dependently Increases Maximal Voluntary Strength and Leg Power, but Does Not Affect Fatigability or Specific Tension J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1478 - 1485. [Abstract] [Full Text] [PDF]

				T. A. Roy, M. R. Blackman, S. M. Harman, J. D. Tobin, M. Schrager, and E. J. Metter Interrelationships of serum testosterone and free testosterone index with FFM and strength in aging men Am J Physiol Endocrinol Metab, August 1, 2002; 283(2): E284 - E294. [Abstract] [Full Text] [PDF]

				A. M. Matsumoto Andropause: Clinical Implications of the Decline in Serum Testosterone Levels With Aging in Men J. Gerontol. A Biol. Sci. Med. Sci., February 1, 2002; 57(2): M76 - 99. [Full Text]

				M. R. Smith, F. J. McGovern, A. L. Zietman, M. A. Fallon, D. L. Hayden, D. A. Schoenfeld, P. W. Kantoff, and J. S. Finkelstein Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer N. Engl. J. Med., September 27, 2001; 345(13): 948 - 955. [Abstract] [Full Text] [PDF]

				A. Vermeulen Androgen Replacement Therapy in the Aging Male--A Critical Evaluation J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2380 - 2390. [Full Text] [PDF]

				P. Taxel, D. G. Kennedy, P. M. Fall, A. K. Willard, J. M. Clive, and L. G. Raisz The Effect of Aromatase Inhibition on Sex Steroids, Gonadotropins, and Markers of Bone Turnover in Older Men J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2869 - 2874. [Abstract] [Full Text] [PDF]

				A. M. Kenny, K. M. Prestwood, C. A. Gruman, K. M. Marcello, and L. G. Raisz Effects of Transdermal Testosterone on Bone and Muscle in Older Men With Low Bioavailable Testosterone Levels J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2001; 56(5): 266M - 272. [Abstract] [Full Text]

				R. S. Swerdloff and C. Wang Androgens, Estrogens, and Bone in Men Ann Intern Med, December 19, 2000; 133(12): 1002 - 1004. [Full Text] [PDF]

				C. Wang, R. S. Swerdloff, A. Iranmanesh, A. Dobs, P. J. Snyder, G. Cunningham, A. M. Matsumoto, T. Weber, and N. Berman the Testosterone Gel Study Group Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men J. Clin. Endocrinol. Metab., August 1, 2000; 85(8): 2839 - 2853. [Abstract] [Full Text]

				H. C. Margolese The Male Menopause and Mood: Testosterone Decline and Depression in the Aging Male--Is There a Link? J Geriatr Psychiatry Neurol, July 1, 2000; 13(2): 93 - 101. [Abstract] [PDF]

				C. W. Martin, S. C. Riley, D. Everington, N. P. Groome, R. A. Riemersma, D. T. Baird, and R. A. Anderson Dose-finding study of oral desogestrel with testosterone pellets for suppression of the pituitary-testicular axis in normal men Hum. Reprod., July 1, 2000; 15(7): 1515 - 1524. [Abstract] [Full Text] [PDF]

				V. Rochira, M. Faustini-Fustini, A. Balestrieri, and C. Carani Estrogen Replacement Therapy in a Man with Congenital Aromatase Deficiency: Effects of Different Doses of Transdermal Estradiol on Bone Mineral Density and Hormonal Parameters J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 1841 - 1845. [Abstract] [Full Text]

				F. Iqbal, J. Michaelson, L. Thaler, J. Rubin, J. Roman, and M. S. Nanes Declining Bone Mass in Men With Chronic Pulmonary Disease* : Contribution of Glucocorticoid Treatment, Body Mass Index, and Gonadal Function Chest, December 1, 1999; 116(6): 1616 - 1624. [Abstract] [Full Text] [PDF]

				R. Bross, M. Javanbakht, and S. Bhasin Anabolic Interventions for Aging-Associated Sarcopenia J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3420 - 3430. [Full Text] [PDF]

				L. Pederson, M. Kremer, J. Judd, D. Pascoe, T. C. Spelsberg, B. L. Riggs, and M. J. Oursler Androgens regulate bone resorption activity of isolated osteoclasts in vitro PNAS, January 19, 1999; 96(2): 505 - 510. [Abstract] [Full Text] [PDF]

				Y. J. H. Janssen, J. Doornbos, and F. Roelfsema Changes in Muscle Volume, Strength, and Bioenergetics during Recombinant Human Growth Hormone (GH) Therapy in Adults with GH Deficiency J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 279 - 284. [Abstract] [Full Text]

				S. Bhasin VIII. Conclusion--Research Design Issues in Examining the Effects of Testosterone Supplementation in Older Men J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3445 - 3448. [Full Text]

				C. Di Somma, A. Colao, A. Di Sarno, M. Klain, M. L. Landi, G. Facciolli, R. Pivonello, N. Panza, M. Salvatore, and G. Lombardi Bone Marker and Bone Density Responses to Dopamine Agonist Therapy in Hyperprolactinemic Males J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 807 - 813. [Abstract] [Full Text]

				S. Arslanian and C. Suprasongsin Testosterone Treatment in Adolescents with Delayed Puberty: Changes in Body Composition, Protein, Fat, and Glucose Metabolism J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3213 - 3220. [Abstract] [Full Text] [PDF]

				H. M. Behre, S. Kliesch, E. Leifke, T. M. Link, and E. Nieschlag Long-Term Effect of Testosterone Therapy on Bone Mineral Density in Hypogonadal Men J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2386 - 2390. [Abstract] [Full Text] [PDF]